Eastern Mediterranean (WHO region) vs Nicaragua: Treatment success rate: XDR-TB cases
Eastern Mediterranean (WHO region)
74
in 2022
Nicaragua
100
in 2021
Eastern Mediterranean (WHO region) rank
1st
Nicaragua rank
1st
Treatment success rate: XDR-TB cases over time
- Eastern Mediterranean (WHO region)
- Nicaragua
How they compare
Nicaragua currently reports 100 against 74 in Eastern Mediterranean (WHO region), a difference of 26.
That makes Nicaragua's figure about 1.4 times Eastern Mediterranean (WHO region)'s.
The two have swapped places 2 times across 5 shared years of data; in 2015 it was Nicaragua ahead.
Eastern Mediterranean (WHO region) ranks 1st and Nicaragua ranks 1st of 11 groups.
Across the 2 decades both report, Eastern Mediterranean (WHO region) averaged higher in 1 and Nicaragua in 1.
Head to head by decade
| Decade | Eastern Mediterranean (WHO region) | Nicaragua | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 38.33 | 100 | 61.67 | Nicaragua |
| 2020s | 71 | 50 | 21 | Eastern Mediterranean (WHO region) |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher treatment success rate: xdr-tb cases, Eastern Mediterranean (WHO region) or Nicaragua?
- Nicaragua, at 100 against 74 in Eastern Mediterranean (WHO region) as of 2021.
- What is the difference in treatment success rate: xdr-tb cases between Eastern Mediterranean (WHO region) and Nicaragua?
- 26, with Nicaragua ahead.
- How many years of comparable data are there for Eastern Mediterranean (WHO region) and Nicaragua?
- 5 years are reported by both, from 2015 to 2021.
- How do Eastern Mediterranean (WHO region) and Nicaragua rank globally for treatment success rate: xdr-tb cases?
- Eastern Mediterranean (WHO region) ranks 1st and Nicaragua ranks 1st of 11 groups.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Treatment success rate: XDR-TB cases. Statizoid refreshes it automatically from the source and publishes the full history for both places.